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Background: Evidence suggests that high dose haemodialysis (HD) may be associated with better health
outcomes and even cost savings (if conducted at home) versus conventional in-centre HD (ICHD). Home-based
regimens such as peritoneal dialysis (PD) are also associated with significant cost reductions and are more convenient
for patients. However, the financial impact of increasing the use of high dose HD at home with an increased tariff is
uncertain. A budget impact analysis was performed to investigate the financial impact of increasing the proportion
of patients receiving home-based dialysis modalities from the perspective of the England National Health Service
(NHS) payer.
Methods: A Markov model was constructed to investigate the 5 year budget impact of increasing the proportion of
dialysis patients receiving home-based dialysis, including both high dose HD at home and PD, under the current
reimbursement tariff and a hypothetically increased tariff for home HD (£575/week). Five scenarios were compared
with the current England dialysis modality distribution (prevalent patients, 14.1% PD, 82.0% ICHD, 3.9% conventional
home HD; incident patients, 22.9% PD, 77.1% ICHD) with all increases coming from the ICHD population.
Results: Under the current tariff of £456/week, increasing the proportion of dialysis patients receiving high dose
HD at home resulted in a saving of £19.6 million. Conducting high dose HD at home under a hypothetical tariff of
£575/week was associated with a budget increase (£19.9 million). The costs of high dose HD at home were totally
offset by increasing the usage of PD to 20–25%, generating savings of £40.0 million – £94.5 million over 5 years
under the increased tariff. Conversely, having all patients treated in-centre resulted in a £172.6 million increase in
dialysis costs over 5 years.
Conclusion: This analysis shows that performing high dose HD at home could allow the UK healthcare system to
capture the clinical and humanistic benefits associated with this therapy while limiting the impact on the dialysis
budget. Increasing the usage of PD to 20-25%, the levels observed in 2005-2008, will totally offset the additional
costs and generate further savings.
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End-stage renal disease (ESRD) is defined as the most
severe stage of chronic kidney disease (i.e. stage 5,
glomerular filtration rate <15 mL/min/1.73 m2 or on
dialysis) [1]. The treatment of choice for ESRD is kidney
transplantation, but as this is not always feasible largely
due to a shortage of suitable donor kidneys, many ESRD
patients require renal replacement therapy (RRT) in the* Correspondence: Xiaoqing_liu@baxter.com
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unless otherwise stated.form of dialysis in order to survive [2]. Globally, ESRD
presents a significant public health concern. Latest
figures for the UK show that there were 54,824 adults
receiving RRT by the end of 2012; 50% had a functioning
transplant while 50% were receiving dialysis [3]. In
2012, the RRT incidence rate in the UK was 108 per million
population [4].
Haemodialysis (HD) and peritoneal dialysis (PD) are
the two main dialysis treatment options available [5]. PD is
performed at home, either overnight (automated peritoneal
dialysis [APD]) or during the day (continuous ambulatoryThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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for Health and Care Excellence (NICE) recommends
that PD should be considered as the first choice of
dialysis modality in suitable adult patients as it offers
more flexibility, improves preservation of residual renal
function and can lead to a survival benefit in the short
term [6]. HD is currently the most widely used dialysis
modality and is usually carried out in a hospital or satellite
unit (in-centre HD [ICHD]), although it can be performed
at home in suitable patients (home haemodialysis
[home HD]) [7,8]. Conventional HD involves three
sessions per week, each lasting 3–5 hours; high dose
HD refers to a regimen of HD in which the frequency
and/or duration of HD sessions either at home or in-centre
is increased [9]. High dose HD avoids the 2 day interval
between dialysis sessions experienced by the majority of
patients receiving conventional HD [10]. Higher rates of
mortality (all-cause and cardiac related causes), stroke and
congestive heart failure have been observed in dialysis
patients on the day following the 2 day interval between
dialysis sessions [10]. Reductions in mortality of 36–61%
have been reported in patients receiving five or more
sessions/week of dialysis versus conventional ICHD
[11-13]. In addition, there is evidence from two randomised
controlled trials (RCTs) demonstrating that high dose HD
has significant benefits including statistically significant
improvements in left ventricular mass and patient quality
of life (QoL) compared with conventional three times
weekly HD [14,15]. A third RCT reported a non-significant
reduction in left ventricular mass and improvements
in patient QoL measures [16]. High dose HD is also
associated with improvements in patient physical and
emotional wellbeing [17,18].
Ultimately, a patient’s choice of dialysis regimen is
influenced by personal preferences, availability of options
within a service, clinical contraindications and economic
factors, including reimbursement issues [5].
The provision of treatments for patients with ESRD is
costly. In 2009–10, it was estimated that the cost of
chronic kidney disease to the National Health Service
(NHS) in England was £1.44–£1.45 billion, more than half
of which was spent on RRT, and which accounted for
approximately 1.3% of the total England NHS spending
for that year [19]. The economic burden of dialysis on
the NHS budget is expected to increase as the rising
incidences of diabetes, hypertension and cardiovascular
disease will likely lead to an increase in ESRD [20]. In a
recent cost-effectiveness analysis conducted from a
UK payer perspective, it was demonstrated that, even
when the current tariff was substantially increased to
be consistent with ICHD (where reimbursement is based
on the frequency of dialysis sessions), high dose HD is
cost-effective when performed at home (but not in-centre)
compared with conventional ICHD [21,22]. However, ahigher tariff will increase the costs of dialysis care and
these costs will not be totally offset by savings in transpor-
tation and medication costs. One way of further offsetting
the cost may be to increase the proportion of patients
receiving PD, considering the lower cost of PD which has
been demonstrated in a multicentre UK study. The mean
annual per-patient costs of providing PD were reported to
be 38–56% lower than the cost of providing conventional
ICHD [23]. Neil et al. used budget impact analysis to esti-
mate the 5 year financial impact of changing the distribution
of dialysis modalities in eight countries (including the UK)
with varying incomes. Assuming utilisation shifts from HD
to PD across all countries, the study reported that, even in
developing countries, increasing the use of PD could
significantly reduce costs compared with HD [8]. However,
the budget impact analysis conducted by Neil and
colleagues only considered PD and did not include home
HD or high dose HD at home [8].
Our study estimated the 5 year budget impact of varying
the current distribution of dialysis regimens, including PD
and high dose HD at home, from the perspective of the
England NHS payer. Specifically, we aimed to explore the
financial impact of increasing the proportion of patients
receiving home-based dialysis both under the current
Payment-by-Results (PbR) tariff and with an increased
tariff for high dose HD at home. In addition, we assessed




A Markov model was constructed using Microsoft Excel®
2010 to explore the financial impact of varying the current
distribution of dialysis modalities. Markov models have
been used to model dialysis treatment in previous eco-
nomic analyses and are widely accepted to be suitable for
modelling chronic conditions [2,24]. Model structure and
data inputs were informed by a review of previous RRT
economic evaluations [24-26], UK Renal Registry annual
reports, the European Renal Association European Renal
Dialysis and Transplant Association (ERA-EDTA) registry
report and NHS PbR tariffs.
The model comprises a number of discrete health
states through which patients can transition. Possible
movements are indicated by arrows in Figure 1. To
ensure consistency in calculations, the model adopts
28-day cycles. Due to their sensitivity to likely changes in
health states, short model cycles are preferable in this
disease area [24,26]. Patient movements are made at the
end of each cycle whereupon they can remain on their
current modality, change to another modality, undergo a
kidney transplant or die. Only one movement is allowed
per cycle and patients can die in any state. Patients may
undergo a kidney transplant at any time in the model.
Figure 1 Model flow diagram. Each dialysis modality is a separate health state in the model as follows: conventional in-centre haemodialysis
(ICHD), performed in hospital or a satellite unit; home-based dialysis, includes peritoneal dialysis (PD) and its sub-modalities, continuous ambulatory
peritoneal dialysis (CAPD), automated peritoneal dialysis (APD), and home haemodialysis, both conventional and high dose; transplant; post-transplant.
Patients can die from any of the health states in the model. One way arrows indicate that patients can only move in one direction while the two way
arrows indicate that patients can move in either direction.
Liu et al. BMC Nephrology 2014, 15:161 Page 3 of 12
http://www.biomedcentral.com/1471-2369/15/161Patients stay in the transplant health state for one cycle,
following which they move to the post-transplant state.
Patients remain in the post-transplant state until either
graft failure occurs and they return to dialysis or they die.
Based on the UK Renal Association recommendations
[27], the model assumes that conventional ICHD consists
of three × 4 hour sessions per week. In this budget impact
analysis, high dose HD at home comprises five × 4 hour
or longer sessions per week. PD is performed daily.
Population data
The model considers prevalent and incident adult
(aged ≥18 years) patients in England diagnosed with
ESRD and requiring dialysis. The size of the prevalent
and incident patient populations entering the model
in each year is based on epidemiology data taken
from the UK Renal Registry 16th Annual Report [3,4].
Model input data
Survival
The model considers how patient survival may differ
between different treatment modalities. As the UK renal
registry only provides summary statistics of patient
survival, patient survival in the model is based on
survival curves from the ERA-EDTA Annual Report
2009 [28]. The report contains age and gender-adjusted
survival data relating to European patients on dialysis
which permits parametric modelling of survival. When
compared to data published by the ERA-EDTA (Europe)
[29], the age and gender distribution of UK patients was
found to be comparable to those patients in other European
countries. Therefore, ERA-EDTA data was deemed
appropriate to use in the model to approximate UK
data. As patient survival may differ between dialysis
modalities, a mortality hazard ratio of 0.76 for high dose
HD versus conventional HD was estimated based on
the literature [9,30,31] (Table 1). These studies reported
mortality hazard ratios and were felt to have sufficientlyadjusted for patient covariates that have the potential to
bias results. Due to a lack of data, survival of HD patients
was not assumed to vary with the dialysis setting, i.e.
receiving dialysis at home was not assumed to confer a
survival benefit. Survival of transplant patients was based
on patient survival data reported by NHS Blood and
Transplant in their activity report for 2012/13 [32].
All cause hospitalisations
The model assumes that, each cycle, a proportion of
patients require hospitalisation due to both dialysis compli-
cations and other health reasons. We consider total costs
to the payer in the model and hospitalisation is a major cost
for dialysis patients. Also, as all-cause hospitalisations were
reported in the earlier Frequent Haemodialysis Network
(FHN) trials, all-cause hospitalisation probabilities were
sourced from FHN publications [14,16]. The FHN publica-
tions contained no data on all-cause hospitalisations in PD
patients, so a weighted ratio of PD to HD all-cause hospita-
lisations was estimated using the study by Lafrance et al.
[34] and data from the USRDS 2012 report [35]. This ratio
was applied to the probability of all-cause hospitalisations
for patients receiving conventional ICHD in the first year
to derive the probability for patients on PD (Table 1). Since
the FHN studies followed patients for 1 year we were
required to make assumptions about how the number of
hospitalisations changes in subsequent years for patients on
HD and PD. A ratio of 0.69 all-cause hospitalisation for
follow-up years versus year one was calculated for HD
patients based on the retrospective study considering
hospital utilisation (including number of hospitalisations
and hospital days per patient per year at risk) among
dialysis patients from 1992–97 reported by Arora et al.
[33]. In PD patients in the same study no difference was
observed in hospitalisation rates between the first three
months on dialysis and subsequent months. These study
findings were deemed to be appropriate for use in the
current analysis in the absence of more recent data.
Table 1 Model data inputs
Parameter Value (range) Data sources
Mortality
High dose HD mortality HR vs. conventional HD 0.76 (0.57-0.95) Johansen; Marshall; Nesrallah [9,12,13]
Home HD mortality HR vs. ICHD 1.00 Assumption
Hospitalisations (28 day probabilities)
Conventional ICHD Year 1: 7.05% (5.29% - 8.81%) Year 1: FHN trial [14]
Year 2+: 4.86% (3.65% - 6.08%) Year 2+: Arora† [33]
Conventional home HD Year 1: 5.35% (4.01% - 6.68%) Year 1: FHN trial [14]
Year 2+: 3.69% (2.77% - 4.61%) Year 2+: Arora† [33]
High dose HD at home Year 1: 7.09% (5.32% - 8.86%) Year 1: Rocco [16]
Year 2+: 4.89% (3.67% - 6.11%) Year 2+:Arora† [33]
All PD Year 1: 6.69% (5.02% – 8.36%) Year 1: Lafrance , USRDS [34,35]
Year 2+: 6.69% (5.02% - 8.36%) Year 2+: Arora† [33]
Transition probabilities (28 days)
Transplant rate – all modalities 0.007 (0.005 – 0.009) UK Renal Registry reports [36,37],
Graft failure probability – all modalities 0.004 (0.003 – 0.005) NHS Blood and Transplant Activity Report for 2012-13 [32]
Proportion moving from ICHD - > home HD
0 – 12 months 0.05% (0.04% - 0.06%) Assumption
13 – 18 months 0.03% (0.02% - 0.04%)
19+ months 0%
Proportion moving from home HD - > ICHD
Constant probability 0.38% (0.29% - 0.48%) McFarlane [38]
Proportion moving from HD - > PD
0 – 6 months Incident: 1.95% (1.46% - 2.44%) Johnson, Haller [39,40]
Prevalent: 1.08% (0.81% - 1.35%)
7 – 12 months 0.20% (0.15% - 0.25%)
13 – 18 months 0.07% (0.05% - 0.08%)
19+ months 0.06% (0.04% - 0.07%)
Proportion moving from PD - > HD
0 – 6 months Incident: 2.61% (1.96% - 3.26%) Johnson, Haller [39,40]
Prevalent: 1.87% (1.40% - 2.34%)
7 – 12 months 1.13% (0.85% - 1.41%)
13 – 18 months 0.78% (0.59% - 0.97%)
19+ months 0.31% (0.23% - 0.39%)
Abbreviations: HD Haemodialysis, HR Hazard ratio, ICHD In-centre haemodialysis, PD Peritoneal dialysis.
†Hospitalisation rates in years 2+ are based on a ratio of first year to subsequent year hospitalisations estimated from data from Arora [33].
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Patients can change dialysis modalities at any point during
the model. Reasons for changing include complications
and changes in treatment preferences. Estimated probabil-
ities of changing modality were derived from the literature
and from Baxter UK PD patient follow-up data (Table 1).
The default probabilities of patients changing from HD to
PD are averages across the studies by Johnson and Haller
[39,40]. The model assumes that patients do not change
within specific modalities, i.e. between different types of
PD. However, patients may change from ICHD to homeHD and vice versa. When a patient changes dialysis
modality they are redistributed according to the baseline
distribution of the modality to which they change. Patients
starting HD may start on conventional or high dose
HD; the proportions are setting-specific. The prob-
ability of a patient remaining in the same health state
from one cycle to the next is taken to be equal to 1
minus the probability of them moving to another state. In
the event of graft failure, the patient returns to dialysis
and their dialysis setting is dependent on the baseline
patient distribution.
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The budget impact analysis is conducted from the
perspective of the payer in the England NHS. As such,
PbR tariffs, which represent the fixed reimbursement
payments made by payers to providers for procedures
undertaken, and are based on national average costs
from previous years, are used for estimating costs of
providing RRT for ESRD patients. The tariff for ICHD
is a cost per session whereas the home HD tariff is a
fixed weekly tariff and does not vary with the number
of dialysis sessions conducted per week (the original
tariff was calculated on the basis of 3 sessions per
week). The model considers the following cost ele-
ments associated with ESRD treatment: dialysis access
establishment and maintenance [41], dialysis services
[41], patient monitoring [41], all-cause hospitalisations
[41,42], erythropoiesis-stimulating agents (ESAs) [36,43],
transportation to and from clinics [44-46], and kidney
transplantation and its maintenance [47,48]. In line with
International Society for Pharmacoeconomics and
Outcomes Research (ISPOR) current guidelines for budget
impact, costs were not discounted in the analysis
[49]. Details of the costs elements and sources of data
are shown in Table 2.
Budget impact analysis
The economic model was constructed to explore the
financial impact of: (1) increasing the proportion of
patients receiving home-based dialysis under the
current reimbursement tariff, (2) the financial impact
of increasing the proportion of patients receiving
home-based dialysis with an increased reimbursement
tariff for high dose HD at home and (3) the financial
consequences of no patients receiving home-based
dialysis. All analyses were conducted from the England
NHS perspective. The budget impact analysis allows for
the consideration of both incident and prevalent patients
entering the model over a 5 year time horizon. A prevalent
population size of 22,993 patients [3] was modelled with
annual incident populations of 5,395 patients [4] entering
the model in years 2–5. The data inputs in the model were
used to calculate the current and future costs for
patients on dialysis up to a maximum of 5 years from
baseline. The modalities examined in this analysis were
conventional ICHD, PD, conventional home HD and high
dose HD at home.
As shown in Table 3, a reference scenario representing
the current England dialysis modality distribution [3,4]
was compared with five hypothetical scenarios in which
the numbers of prevalent and incident patients receiving
home-based dialysis were varied. In each scenario, the
proportion of patients on ICHD changes to compensate
for the increase in the proportion of patients receiving
PD and high dose HD at home. The increases in thenumbers of PD patients to 20–25% in the scenario ana-
lyses were based on the number of UK patients reported
to be receiving PD from 2005-2008 [53-56] while 39% of
incident patients receiving PD is used as this is the opti-
mal level defined by NICE [6]. With the exception of
scenario 5, the proportion of patients receiving conven-
tional home HD is kept constant. The percentage of
incident patients receiving home HD is set to zero
because in usual clinical practice, incident patients do
not start on home HD. In addition to the analysis under
the current PbR tariff, another analysis was conducted
where the home HD tariff was increased to £575. This was
in order to be comparable to ICHD, where reimbursement
is based on the number of dialysis sessions.
Results
The size of the prevalent and incident patient populations
entering the model in each year over a 5 year time horizon
was based on epidemiology data. The 5 year accumulated
budget impact results for the entire patient cohort in each
scenario are presented in Table 4. These represent the
costs incurred by both prevalent and incident patients
who have entered the model up to that point. The budget
impact results on a per-patient basis averaged over 5 years
are shown in Table 5. Per-patient calculations are based
on the number of patients who have entered the model up
to that point. In scenario 1, wherein a larger proportion of
prevalent patients were receiving high dose HD at home
(10%), the overall projected costs were lower compared to
the reference scenario (current practice in England) due
to savings made with transportation costs. Over 5 years,
scenario 1 was associated with a saving of £20 million
(£439 per patient) while the overall cumulative budget
impact, relative to the reference scenario was -0.50%. In
scenario 2, increasing high dose HD at home to 10% in
prevalent patients under an increased PbR tariff of £575
resulted in increased costs across all cost components
with the exception of transportation costs. Over 5 years,
scenario 2 was associated with higher projected costs of
£20 million (£447 per patient) while the overall cumulative
budget impact, relative to the reference scenario was
0.51%. In scenario 3, increasing the number of prevalent
high dose HD at home and PD patients to 10% and 20%,
respectively and increasing the proportion of incident
patients receiving PD (31%) with an increased PbR tariff
of £575 for high dose HD at home was associated with a
total saving of £40 million (£898 per patient) over 5 years.
Compared with the reference scenario, scenario 3 was
associated with lower ESA and transportation costs.
The overall cumulative budget impact for scenario 3
was -1.03%. In scenario 4, where the number of prevalent
patients receiving high dose HD at home was increased to
10% (with a PbR tariff of £575), and prevalent and incident
PD patients were increased to 25% and 39%, respectively
Table 2 Cost elements considered in the model
Parameter Value (range) Data sources
Access costs
Vascular access cost £1,287 (£965 - £1,609) PbR tariff 2013-2014 [41]
Peritoneal access costs (PD specific) £1,233 (£854 – £1,423) PbR tariff 2013-2014 [41]
Dialysis service costs
ICHD cost per session
Catheter access £121 (£92 - £154) PbR tariff 2013-2014 [41]
AV fistula/graft access £152 (£115 - £191)
Weighted £147 Breakdown based on the target percentage set by
the best practice tariff for 2013/14 [50]
Home HD cost per week £456 (£342 - £570) PbR tariff 2013-2014 [41]
PD cost per day
APD £52 (£39 - £65) PbR tariff 2013-2014 [41]
CAPD £46 (£35 - £58)
ESA costs
ESA cost per 1,000 units Dose (units/week) £5.09 (£3.82 - £6.36) BNF No. 64 [43]
HD (all sub-modalities) 6,705 (5,029 – 8,381) Rao [51]
PD (all sub-modalities) 3,700 (2,775 – 4,625) Rao [51]
Monitoring costs†
Single professional £132 (£99 - £165) PbR tariff 2013-2014 [41]
Multi professional £247 (£185 - £309)
Weighted £190 Equal weighting assumed.
Hospitalisation costs
HD hospitalisation £1,904 (£1,482 - £2,380) Event costs from the PbR tariff 2013-2014 [41]. Event numbers
from the National Schedule of Reference Costs 2011-12 [42]
PD hospitalisation £1,596 (£1,197 - £1,995)
Transport cost per visit
ICHD sessions‡ £46 Breakdown based on the National Kidney Care Audit, Patient
Transport Survey 2010 [45]
Transplant costs§
Transplant procedure cost £18,579 National Schedule of Reference Costs 2012-13 [48] Breakdown
based on the NHS Blood and Transplant Activity Report for 2012-13 [32]
Post-transplant medication costs £11,137 (£8,352 - £13,921) NHS Kidney Care report [47]
Abbreviations: APD Automated peritoneal dialysis, CAPD Continuous ambulatory peritoneal dialysis, CC Complications or comorbidity, ESA Erythropoiesis
stimulating agents, HD Haemodialysis, ICHD In-centre haemodialysis, PD Peritoneal dialysis.
†Patients on each modality are assumed to receive two monitoring visits/year.
‡Breakdown of transport costs are as follows: ambulance service vehicle - £189 (£142 - £236) [46]; Hospital-provided car £27 (£20 - £34) [45]; Hospital-arranged taxi
£31 (£23 - £39) [45]; Hospital transport vehicle £13 (£10 - £16) [52]; public £5 (£4 - £6), based on assumption; private £5 (£4 - £6), based on assumption.
§Breakdown of transport costs are as follows: donor after brain death £19,804 (£14,853 - £24,755) [48]; donor after cardiac death £16,580 (£12,435 - £20,725)
[48]; living donor £18,640 (£13,980 - £23,300) [49].
Liu et al. BMC Nephrology 2014, 15:161 Page 6 of 12
http://www.biomedcentral.com/1471-2369/15/161(under the current tariff ), the 5 year projected total cost
savings were £94 million (£2,119 per patient). The overall
cumulative budget impact, relative to the reference
scenario was -2.44%. Total cost savings in scenario 4 were
specifically impacted by lower projected transportation
costs over 5 years (a saving of £102 million). In scenario 5,
where 100% of patients received ICHD, 5 year projected
total costs were £173 million higher than the reference
scenario (£3,872 per patient) with an overall cumulative
budget impact of 4.45%. Scenario 5 was associated withhigher costs across all individual cost components with
the exception of monitoring costs that were marginally
lower.
With the exception of scenario 5, all scenarios were
associated with lower projected transportation costs over
5 years. Increasing the use of high dose HD at home
(scenarios 1–4) and PD (scenarios 3 and 4) over 5 years
would result in projected savings in transportation costs
of £37 million (scenarios 1 and 2), £71 million (scenario 3)
and £102 million (scenario 4).
Table 3 Current UK dialysis modality distribution and patient distribution scenarios considered in the budget impact
analysis




Reference scenario 14.1 82.0 0.0 3.9 0.0 Current
Scenario 1 14.1 72.0 0.0 3.9 10.0 Current
Scenario 2 14.1 72.0 0.0 3.9 10.0 High dose HD at home:
increased to £575.
All other modalities: current
Scenario 3 20.0 66.1 0.0 3.9 10.0 High dose HD at home:
increased to £575.
All other modalities: current
Scenario 4 25.0 61.1 0.0 3.9 10.0 High dose HD at home:
increased to £575.
All other modalities: current
Scenario 5 0.0 100.0 0.0 0.0 0.0 Current
Incident patients (%)
Reference scenario 22.9 77.1 0.0 0.0 0.0 Current
Scenario 1 22.9 77.1 0.0 0.0 0.0 Current
Scenario 2 22.9 77.1 0.0 0.0 0.0 Current
Scenario 3 31.0 69.0 0.0 0.0 0.0 Current
Scenario 4 39.0 61.0 0.0 0.0 0.0 Current
Scenario 5 0.0 100.0 0.0 0.0 0.0 Current
Abbreviations: HD Haemodialysis, ICHD In-centre haemodialysis, PbR Payment-by results, PD Peritoneal dialysis.
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averaged over 5 years are shown in Table 5. The results
show that the relative budget impact on a per patient basis
is broadly in line with the total cohort results shown in
Table 4. As demonstrated for the total cohort, scenarios 1,
3 and 4 were associated with lower, average projected per
patient/year costs with the greatest savings shown in
scenario 4 (cost savings of £572 per patient relative to the
reference scenario). Scenarios 2 and 5 were associated
with increased projected average per patient costs (cost
per patient increases of £117 and £1,043, respectively).
Discussion
This analysis demonstrated that increasing the proportion
of patients on home-based dialysis modalities is associated
with a lower total financial burden to the payer under the
current PbR tariff. When an increased PbR tariff for high
dose HD at home comparable to high dose HD in-centre
is assumed, the associated increased cost to the payer
could be offset by increasing the proportion of patients
receiving PD, which is associated with a lower PbR tariff
than HD. However, if no patients receive home-based
dialyses, the total burden to the payer would be much
higher over 5 years.
To the best of our knowledge, this is the first England-
specific study that has used budget impact analysis toforecast how altering the conventional distribution of
dialysis modalities could potentially reduce the total
financial burden to the payer of providing and sup-
porting the continually growing demand for dialysis
services in England.
The cost savings that were projected over the 5 years
in this study were driven by lower transportation costs
associated with home-based dialyses and with ESA cost
reductions for patients on PD versus HD. Although ESA
and transport costs are not included in the current UK
tariff, these costs are paid to dialysis providers or
reimbursed directly to patients by the NHS in addition to
the dialysis tariff and are therefore included in the analysis.
The National Kidney Foundation reports that dialysis
accounts for up to 50% of patient transport service costs
across 52 hospitals in England while £49.5 million of
spending by the NHS in 2009–10 was attributable to
dialysis transport costs [57]. Our results demonstrate
that considerable savings in the transportation costs
related to dialysis services could be made by the
payer by increasing the uptake of home-based dialysis
regimens. Note also that the current fixed home HD
tariff covers initial training and any necessary home
modification costs. It is designed such that the dialysis
provider is able to recover their initial investment over
time. With respect to ESA costs, the latest data from the
Table 4 Five-year cumulative budget impact results for the entire cohort (reference scenario versus scenarios 1–5)
Difference
Reference scenario (£) Scenario 1 (£) Scenario 2 (£) Scenario 3 (£) Scenario 4 (£) Scenario 5 (£)
Access costs 67,573,647 64,236 (0.10%) 64,236 (0.10%) −772,145 (-1.14%) −1,533,465 (-2.27%) 2,162,385 (3.20%)
Treatment costs 2,818,006,173 15,825,109 (0.56%) 55,320,485 (1.96%) 34,513,656 (1.22%) 15,651,634 (0.56%) 56,467,306 (2.00%)
ESA costs 173,328,756 755,080 (0.44%) 755,080 (0.44%) −3,477,002 (-2.01%) −7,316,930 (-4.22%) 10,903,915 (6.29%)
Monitoring costs 49,553,898 191,026 (0.39%) 191,026 (0.39%) 303,374 (0.61%) 405,098 (0.82%) −288,277 (-0.58%)
Complication costs 147,756,210 582,276 (0.39%) 582,276 (0.39%) 312,811 (0.21%) 48,730 (0.03%) 1,490,818 (1.01%)
Transportation costs 620,677,229 −36,982,815 (-5.96%) −36,982,815 (-5.96%) −70,900,727 (-11.42%) −101,706,432 (-16.39%) 101,841,215 (16.41%)
Total costs 3,876,895,913 −19,565,088 (-0.50%) 19,930,289 (0.51%) −40,020,032 (-1.03%) −94,451,365 (-2.44%) 172,577,361 (4.45%)
























(current home HD tariff)
23,187 - -
Scenario 1 23,038 −149 −0.64%
Scenario 2 23,304 117 0. 50%
Scenario 3 22,941 −246 −1.06%
Scenario 4 22,615 −572 −2.47%
Scenario 5 24,320 1,043 4.50%
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http://www.biomedcentral.com/1471-2369/15/161UK Renal Registry reports that 87% of HD patients and
69% of PD patients were receiving ESAs in 2012 (median
ESA dose 7,248 IU/week and 4,250 IU/week, respectively)
[58]. The lower ESA costs associated with PD versus HD in
the current analysis is due to a combination of both a lower
prevalence of anaemia and also a lower recommended
weekly dose of ESA treatment in PD patients compared
with HD patients [43]. There is currently no conclusive evi-
dence in the literature reporting significant differences in
erythropoietin doses between dialysis patients receiving
high dose HD and conventional HD [14-16]. Therefore, we
assume the doses reported in the UK Renal Registry 16th
Annual Report can be applied to all patients receiving HD.
High dose HD and home-based dialysis regimens are
associated with improved clinical outcomes and better
QoL for patients. Nocturnal daily HD in particular
demonstrates increased clinical effectiveness, including
better blood pressure control and improved measures
of anaemia, compared with conventional three times
weekly ICHD [59,60]. Liem at al reported that, while
not statistically significant, mean patient QoL was
higher in PD patients compared with conventional ICHD
patients [61]. There is also some evidence that both high
dose and home-based dialysis regimens may confer a
survival advantage compared to conventional ICHD [62,63].
A dose-response relationship has been demonstrated
between the number of hours of dialysis per week
and survival [64]. An observational study reported
that nocturnal HD (5 or 6 days/week) was associated
with a 64% reduction in mortality risk compared with
conventional HD [9]. Five and 10 year survival rates of 93%
and 72%, respectively have previously been reported in
patients receiving home HD compared with rates of 64%
and 48%, respectively in patients receiving conventional
ICHD [62]. In scenarios 3 and 4 in our analysis, where the
proportions of patients receiving high dose HD at home
and PD were increased, we noted that savings were to be
made across all cost components with the exception of
treatment and monitoring costs. This could be attributed
to improved survival rates in those patients receiving high
dose HD at home and PD. Despite the benefits of
home-based HD regimens, the number of patients receivinghome-based dialysis has continued to fall. From 2009–10,
there was a 3.2% decrease in the number of patients
receiving PD in the UK [65]. Similarly, in 2010, only
3% of the total number of RRT patients in the UK
were receiving home HD [65].
Our findings are supported by earlier economic evalua-
tions on this topic. A previous UK NHS economic evalu-
ation suggested that increasing the proportion of patients
on home HD is a cost-effective alternative to conventional
ICHD. However, in contrast to the current analysis, this
NHS analysis did not consider high dose HD at home [26].
Similarly, in 2011, NICE produced a national costing report
that considered the prevalent dialysis population. The report
suggested that if 39% of patients were to receive PD, this
could result in annual savings of £20 million nationally [6].
Recently, the UK Department of Health initiated a
Quality, Innovation, Productivity and Prevention (QIPP)
program that aims to improve the quality and delivery of
NHS care while reducing costs to make £20bn efficiency
savings by 2014/15. For example, it aims to involve
patients more in managing their own conditions and to
treat more patients closer to home so that it may be
possible to reduce the number of costly hospital admissions
[66]. The Home Dialysis Manifesto, 2013 report comments
that it finds the fact that the promotion of home dialysis
has not been made a priority surprising in the context of
the NHS QIPP agenda [57]. In addition, the manifesto
reported that the main obstacles facing the uptake of
home-based dialysis modalities included lack of patient
knowledge of the availability and benefits of home-based
HD, clinical bias and no coordinated national approach to
home-based HD. Other barriers to successful implementa-
tion of home dialysis are reported as business practices of
dialysis providers such as appropriate staffing, availability
of pharmaceuticals and delivery of supplies [67]. It is
acknowledged that choice of dialysis modality is also influ-
enced by patient preferences which are in turn influenced
by factors such as patient age, physical status, presence of
comorbidities and lifestyle [68,69]. PD patients report less
illness intrusion, better renal care and greater independ-
ence and satisfaction [70,71] while HD patients cite bene-
fits of social and staff interaction and fear of social
isolation as reasons for not choosing home HD [68,72].
NICE clinical guideline 125 for PD states that healthcare
professionals should acknowledge that dialysis patients
priorities may differ to their own clinical priorities, thus
treatment decisions should take into account the patient’s
needs and preferences [5]. Although it has been suggested
that 50% of dialysis patients would choose PD if possible
[73], the most recent data from the UK reports that in
2012, PD was used by only 22% and 14% of incident and
prevalent patients, respectively [3,4].
Our model has several strengths, especially in its
approach to costing health states. The earlier PD costing
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http://www.biomedcentral.com/1471-2369/15/161report produced by NICE in 2011 estimated annual
projected cost savings of £20 million and potential
savings of £4 million after 5 years if the number of
patients receiving PD were to increase by 1% each year
[6]. This analysis, however, did not account for patient
mortality or for transitions between different modalities.
In addition, the only cost components considered were
tariff costs and complication costs. Our analysis reflects
the dynamic nature of the dialysis population and
considers multiple additional cost components, including
ESA costs, transport costs and access maintenance costs.
The key drivers in the current budget impact were the
lower ESA and transportation costs, neither of which was
taken into consideration in the NICE report.
There are also limitations associated with our model
used in the current budget impact analysis. Firstly, data
specifically relating to patients in England was not available
for some model inputs such as survival. For the baseline
survival, we used data from the European Registry while
data from observational studies was used for the survival
benefits of high dose HD versus conventional ICHD. As
clinical practices in other countries may differ to those in
England, some of the data inputs in the model may not be
representative of typical clinical practice in England.
Secondly, because the model is constructed from the
England payer perspective, it considers only major costs to
the payer such as dialysis services costs, monitoring costs
and transportation costs. Costs such as productivity losses
or out-of-pocket costs to patients were not included.
Thirdly, due to the lack of available published data, some
of the input values such as the transition rate from ICHD
to home HD have been founded on assumptions based on
expert opinion. Finally, our data is only currently applicable
to adult patients who are suitable and willing candidates
for PD and home-based dialysis.
Despite the encouraging results of the current budget
impact analysis, further high quality research into the
survival and improved quality of life benefits associated
with high dose HD is needed. Well designed, large scale
clinical trials are currently the mainstay of influencing
changes in clinical practice. However, such studies in
ESRD patients may never be conducted due to the nature
of the disease [74].Conclusions
Increasing the uptake of home-based dialysis modalities
could generate substantial cost savings for the England
NHS by savings in transportation and medication costs.
Performing high dose HD at home regimens in particu-
lar would also support the objectives of the QIPP initia-
tive to improve quality of patient care while making
major efficiency savings when simultaneously developed
with PD.Abbreviations
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